Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Orteronel

Generic Name: Orteronel

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₇N_₃O_₂

CAS Number: 566939-85-3

Unique Ingredient Identifier: UE5K2FNS92

Overview

Orteronel has been investigated for the treatment of Prostate Cancer.

Background

Orteronel has been investigated for the treatment of Prostate Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.

Phase 2

Terminated

Posted: 2014/04/02

Sponsor:

Grupo Español de Tum...

ID:NCT02101684

Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)

Phase 1

Withdrawn

Posted: 2014/02/04

Sponsor:

Emmanuel Antonarakis...

ID:NCT02054793

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Phase 3

Withdrawn

Posted: 2014/02/03

Sponsor:Swiss Group for Clin...

ID:NCT02053311

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Phase 2

Completed

Posted: 2013/11/21

Sponsor:SCRI Development Inn...

ID:NCT01990209

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2

Terminated

Posted: 2013/05/31

Sponsor:University of Southe...

ID:NCT01866423

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy